A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder, Mazen Y. Khalil, Daruka Mahadevan, Changchun Deng, Jennifer E. Amengual, Petros G. Nikolinakos, Jill M. Kolesar, John G. Kuhn, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science